Nutlin-3a

For research use only.

Catalog No.S8059 Synonyms: (-)-Nutlin-3

45 publications

Nutlin-3a Chemical Structure

CAS No. 675576-98-4

Nutlin-3a ((-)-Nutlin-3), the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay. Nutlin-3a induces autophagy and apoptosis in a p53-dependent manner.

Size Price Stock Quantity  
USD 248 In stock
USD 844 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Nutlin-3a has been cited by 45 publications

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3a ((-)-Nutlin-3), the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay. Nutlin-3a induces autophagy and apoptosis in a p53-dependent manner.
Features Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.
Targets
p53/MDM2 interaction [3]
(Cell-free assay)
90 nM
In vitro

Nutlin-3a displaces p53 from the binding pocket of MDM2 and thereby releases p53 from inhibition and proteasomal degradation, leading to induction of its downstream targets, cell cycle arrest, and apoptosis. Seven days of incubation with 10 μM nutlin-3a led to >90% inhibition of NIH3T3 cells’ growth[1]. Nutlin-3a stabilizes and activates p53, and induces p21 expression in a dose-dependent manner[1]. Nutlin-3a effectively depletes the S-phase compartment to 0.2-2% and increases the G1- and G2/M-phase compartments[1]. Nutlin-3a induces apoptosis in ~60% of SJSA-1 and MHM cells after 40 h, which increased further after 60 h (85% and 65%, respectively) [1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 MkixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HQSGlEPTB;MD62NVI{PyEQvF2= NVXHSIl4W0GQR1XS
H4 M1XPNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7YTWM2OD1yLk[2Nlgh|ryP M1q5fXNCVkeHUh?=
PA-1 NWnmR5UxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37DVWlEPTB;MD64O|A6PiEQvF2= MnPLV2FPT0WU
NKM-1 NXzvOYx7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLiZWZKSzVyPUGuNFQ6OzFizszN NUjwVotjW0GQR1XS
NEC8 MkLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTFwMkG1O|Ih|ryP NWXy[4FWW0GQR1XS
EoL-1-cell M{TYSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTFwMk[3NFEh|ryP M1TrVHNCVkeHUh?=
K5 M2jLRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoiwTWM2OD1zLkSyNFczKM7:TR?= MVnTRW5ITVJ?
QIMR-WIL MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnPOFd1UUN3ME2xMlYxQDV2IN88US=> MmDyV2FPT0WU
MOLT-16 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrtWY1iUUN3ME2xMlc5PjB2IN88US=> MVrTRW5ITVJ?
CHP-212 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVG0SJpNUUN3ME2xMlgyOzZ7IN88US=> MV\TRW5ITVJ?
CTB-1 Ml32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmm4TWM2OD1{LkCyNlQ3KM7:TR?= NYfzXpVuW0GQR1XS
MOLT-4 NWDobG1sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Do[mlEPTB;Mj6zNlg2OyEQvF2= NULEemt7W0GQR1XS
A101D NFfGXpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzCc|NKSzVyPUKuN|UxOSEQvF2= MXzTRW5ITVJ?
DOHH-2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTJwNEKyO|kh|ryP NFzxXppUSU6JRWK=
ES4 NEPZVmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jB[WlEPTB;Mj60N|E2PSEQvF2= MW\TRW5ITVJ?
SW780 NYjHN4pQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTJwNUC4PFMh|ryP NFz4cXJUSU6JRWK=
VA-ES-BJ M2ruNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTJwNUSxNUDPxE1? NIfBZndUSU6JRWK=
RPMI-8866 M{noSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnL0TWM2OD1{LkW2NlE1KM7:TR?= NFzUZ4tUSU6JRWK=
ML-2 NEnINXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYP4cpAyUUN3ME2yMlU3PTd4IN88US=> MUjTRW5ITVJ?
MSTO-211H NF\USHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTJwNUe0OVEh|ryP NHXsbotUSU6JRWK=
JVM-3 M4G2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\jTWM2OD1{LkW5N|I1KM7:TR?= MX;TRW5ITVJ?
A3-KAW NVzYbFlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLSTWM2OD1{Lk[xPFE5KM7:TR?= M336ZXNCVkeHUh?=
DK-MG MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGSyTGFKSzVyPUKuOlI1PzFizszN M4XmNnNCVkeHUh?=
LNCaP-Clone-FGC MlvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PJVmlEPTB;Mj62OFMyQCEQvF2= MkPmV2FPT0WU
HT-144 M3rKSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nrfmlEPTB;Mj62OFU4PyEQvF2= MmqwV2FPT0WU
NB69 NHfSZ|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XFcWlEPTB;Mj62OVM{PCEQvF2= Ml7KV2FPT0WU
A172 M3raOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTJwNke1PFgh|ryP NFz1dZBUSU6JRWK=
RS4-11 M2PJUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTJwN{K0NFch|ryP MVXTRW5ITVJ?
DU-4475 NIn5VZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfuOJk5UUN3ME2yMlc6PTB{IN88US=> NVfFUXdMW0GQR1XS
SJSA-1 NGPDN4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37Hd2lEPTB;Mj64NlU2PiEQvF2= MnfnV2FPT0WU
BV-173 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\FTWM2OD1{Lki0OFM6KM7:TR?= MX;TRW5ITVJ?
U-2-OS MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTER|FKSzVyPUKuPVExPyEQvF2= NF\ldYtUSU6JRWK=
CHP-134 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vMcGlEPTB;Mj65N|g5OiEQvF2= NILxOm5USU6JRWK=
D-502MG MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfRfZlKSzVyPUKuPVcyPTRizszN M1Hmc3NCVkeHUh?=
KS-1 NF3CXpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XhPWlEPTB;Mz6wNVYzOyEQvF2= MoXBV2FPT0WU
A204 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XwN2lEPTB;Mz6wOVU5QCEQvF2= Mk\FV2FPT0WU
KGN NVHKcmd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXz1OYtXUUN3ME2zMlA5PDl4IN88US=> MonXV2FPT0WU
NCI-H292 NEG0d2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Dzc2lEPTB;Mz6xNlAzQCEQvF2= MVXTRW5ITVJ?
CAKI-1 NVrBPVhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\JTWM2OD1|LkGyOlk1KM7:TR?= MlPHV2FPT0WU
C2BBe1 Moi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTNwMUewNlYh|ryP NFHlR3BUSU6JRWK=
NB10 NY\hT5Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDJTWM2OD1|LkKwPVY3KM7:TR?= NHK3NYNUSU6JRWK=
MHH-NB-11 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1y1ZWlEPTB;Mz6yOlgzPyEQvF2= NW\Rb|R7W0GQR1XS
NCI-SNU-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnSXI9uUUN3ME2zMlI4QDR|IN88US=> NHjuc|dUSU6JRWK=
HCT-116 M1KzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTNwM{CzN|Uh|ryP M2HvV3NCVkeHUh?=
G-401 NYSzTpZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTNwM{[zNlIh|ryP M3K5fXNCVkeHUh?=
MN-60 NVqyWlBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfidIFKSzVyPUOuOFQxQTJizszN M3;3OnNCVkeHUh?=
SW982 M2T0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV[3bm06UUN3ME2zMlUxQDR6IN88US=> M3nRPXNCVkeHUh?=
RKO MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rOc2lEPTB;Mz61N|k{PiEQvF2= M2LFcXNCVkeHUh?=
D-283MED MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rIPGlEPTB;Mz61O|k5PiEQvF2= MVnTRW5ITVJ?
LB996-RCC NGTWW|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTNwNkK1OVgh|ryP NIXMZ2FUSU6JRWK=
A549 MmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfpeI1KSzVyPUOuOlM2PTJizszN NGf3d3dUSU6JRWK=
LB2241-RCC NEewd3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTNwNkW3NFgh|ryP M3OyWHNCVkeHUh?=
SK-HEP-1 NVG2UHpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTNwN{SyPVch|ryP MnHLV2FPT0WU
G-402 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTNwOEC4N|Ih|ryP MkTWV2FPT0WU
GOTO MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTNwOESzN|Mh|ryP NFG5WXJUSU6JRWK=
LOXIMVI NVTJNZhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfkcmxKSzVyPUOuPFU3PzVizszN NWLzcWhGW0GQR1XS
NH-12 MnnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3S5NWlEPTB;ND6wNVk2QSEQvF2= MYHTRW5ITVJ?
CTV-1 NXX3U5VpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX64[XZpUUN3ME20MlA4QTd|IN88US=> M3XZcXNCVkeHUh?=
CP50-MEL-B MnnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LoN2lEPTB;ND6yOFM6OiEQvF2= MXfTRW5ITVJ?
RH-18 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\VRXNKSzVyPUSuNlc4ODZizszN M1jiZXNCVkeHUh?=
NB17 NV7oZ4lRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zxdmlEPTB;ND6zNVc3QCEQvF2= NWHGTJpOW0GQR1XS
A375 MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXTTWM2OD12LkOzOVI1KM7:TR?= M3\m[3NCVkeHUh?=
IST-MES1 M3zTbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnyxTWM2OD12LkSxOFEyKM7:TR?= NFHqXWlUSU6JRWK=
MZ2-MEL NXTMU2p5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzwTWM2OD12LkWwNVU2KM7:TR?= MUfTRW5ITVJ?
CAL-54 MmH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXqclhXUUN3ME20MlU{ODF7IN88US=> NIHvSZNUSU6JRWK=
NCI-H28 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzlTWM2OD12Lk[yO|E4KM7:TR?= MV3TRW5ITVJ?
D-247MG MnHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vvfGlEPTB;ND63OVA4OiEQvF2= MYDTRW5ITVJ?
NCI-H460 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXGNpN[UUN3ME20MlkyOTJ5IN88US=> MoX6V2FPT0WU
MCF7 M4TpPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTVwNESyOFQh|ryP NHGwWZVUSU6JRWK=
697 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjYflEyUUN3ME21MlQ1PTVizszN M{nERXNCVkeHUh?=
ONS-76 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPtTWM2OD13LkW3NFA6KM7:TR?= Mlm3V2FPT0WU
C32 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTVwNkCwNlkh|ryP NVS1O4p6W0GQR1XS
OS-RC-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUm0fIVGUUN3ME21Mlc{QDh5IN88US=> NVPBdJYyW0GQR1XS
MEL-HO NInudW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUX6eGZiUUN3ME21Mlg2PjZ5IN88US=> NHfWS|JUSU6JRWK=
LoVo M3;WW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnL3TWM2OD14LkCxOlI1KM7:TR?= M3rtd3NCVkeHUh?=
AGS NHj5c21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDYTWM2OD14LkG0PFI5KM7:TR?= NGXrbXBUSU6JRWK=
GI-ME-N NUD3[pExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnHUGtTUUN3ME22MlIzPDJzIN88US=> NGHzeYZUSU6JRWK=
H-EMC-SS NYrX[ZVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jKe2lEPTB;Nj6zPFYh|ryP M{PsOXNCVkeHUh?=
RVH-421 MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfoSpNKSzVyPU[uOFI1OjhizszN MXvTRW5ITVJ?
SW954 NHfwOFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXiT5dOUUN3ME22MlU2PTd{IN88US=> NEnIU3lUSU6JRWK=
NB5 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PKZ2lEPTB;Nj61OlE5OyEQvF2= MULTRW5ITVJ?
NCI-H2122 M3vWcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjDTWM2OD14LkW4O|k{KM7:TR?= NHG5cmdUSU6JRWK=
AM-38 NUjIVm5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPXT3RQUUN3ME22Mlc2PjN7IN88US=> NV;ufpA1W0GQR1XS
KNS-81-FD M3vXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnpToVKSzVyPU[uO|Y1QTRizszN NV;GS2wxW0GQR1XS
LS-513 NEfZOZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfPWmJsUUN3ME22Mlc6ODJ4IN88US=> M13hZnNCVkeHUh?=
A427 NEi3T45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmizTWM2OD14Lki3PFI6KM7:TR?= M2X6TXNCVkeHUh?=
WM-115 NUnjSFBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Px[GlEPTB;Nj65N|I{KM7:TR?= M{jSZ3NCVkeHUh?=
COLO-829 NYX0NWduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDwbpRKSzVyPUeuNlQyQDhizszN NGThRpZUSU6JRWK=
NCI-H1650 NX;zR4tWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHS0RpJKSzVyPUeuN|kzOjhizszN NITyTYJUSU6JRWK=
NCI-H358 MlTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTdwNES4O|kh|ryP M3r5V3NCVkeHUh?=
HT-1080 NVLsOZFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzBTWM2OD15LkS4NlU1KM7:TR?= NHXhZpBUSU6JRWK=
HCC2218 MlnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjmeFVKSzVyPUeuOlI6PyEQvF2= NYnETXhHW0GQR1XS
NCI-H661 MmDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUT4XoJTUUN3ME23Mlg4ODZ7IN88US=> Mn;IV2FPT0WU
KM-H2 NEDkbHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDnTWM2OD15Lki4Olk1KM7:TR?= NHPU[mFUSU6JRWK=
RPMI-2650 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTdwOUS0NVQh|ryP MkfwV2FPT0WU
NCI-H226 NUHBZ2x7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRThwMkGxNlIh|ryP MVLTRW5ITVJ?
MKN45 NGDC[5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUP6blB2UUN3ME24MlI3PjB{IN88US=> MkHiV2FPT0WU
D-392MG NF;OVIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjYPJRKSzVyPUiuOVI4OjJizszN NIDjT4lUSU6JRWK=
RCC10RGB Ml7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRThwOE[2PVUh|ryP MkDXV2FPT0WU
CAL-51 MoXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlu5TWM2OD17LkGwNlUyKM7:TR?= NUnWTWRxW0GQR1XS
COLO-678 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{e0[2lEPTB;OT6zNlgyOSEQvF2= MnnOV2FPT0WU
SK-MEL-24 MkfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13B[WlEPTB;OT61OVg2PiEQvF2= NX7Re5FjW0GQR1XS
SK-MEL-30 M1zNV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTlwOUS0O|Yh|ryP M124cnNCVkeHUh?=
MMAC-SF NWLTd5R4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXIZ3hKSzVyPUGwMlM6PjFizszN MoG1V2FPT0WU
NTERA-S-cl-D1 NWH3WXlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTFyLk[1NFgh|ryP MkXGV2FPT0WU
NB12 NH7jdFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXjdopiUUN3ME2xNU42ODNizszN NVz3U49jW0GQR1XS
UACC-257 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Hz[2lEPTB;MUGuPFY6PSEQvF2= NXXCU4xLW0GQR1XS
LAN-6 M33UcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDwTWM2OD1zMT65PVI5KM7:TR?= NX3CWXNoW0GQR1XS
SW1573 NWnoW4dTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLnXGt{UUN3ME2xNk4{ODh4IN88US=> MnP3V2FPT0WU
NMC-G1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPhSXJKSzVyPUGyMlQyPzVizszN M2XycHNCVkeHUh?=
SHP-77 MlK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLTTWM2OD1zMj61OVc1KM7:TR?= NG[5WFVUSU6JRWK=
IGROV-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;NTWM2OD1zMj62OVc{KM7:TR?= MWLTRW5ITVJ?
22RV1 NGHSWJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELPPZNKSzVyPUGyMlgxPTlizszN Mn7GV2FPT0WU
SK-MEL-3 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDKblJKSzVyPUGzMlM6PzNizszN MVzTRW5ITVJ?
NCI-H1563 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M164VWlEPTB;MUOuOFIxOiEQvF2= M1PCNnNCVkeHUh?=
IGR-1 NXHLdlN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn33TWM2OD1zND6wN|Q4KM7:TR?= MUHTRW5ITVJ?
EW-3 NE\FdHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;OVIViUUN3ME2xOE4yPjN7IN88US=> MlSwV2FPT0WU
JEG-3 M13wcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlG1TWM2OD1zND60PVU{KM7:TR?= MXHTRW5ITVJ?
ES3 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LNbWlEPTB;MUSuOlU3OiEQvF2= MoXJV2FPT0WU
MDA-MB-175-VII NF;vUZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDx[2F5UUN3ME2xOE44OTFzIN88US=> M{CyPHNCVkeHUh?=
P30-OHK NH3iO2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXaW|BKSzVyPUG1MlA1QTZizszN MmfTV2FPT0WU
GP5d M1uye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;TTWM2OD1zNT6xOFY3KM7:TR?= NH[4VGtUSU6JRWK=
HMV-II NX62eXhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTF3LkOzN|Mh|ryP NISzXJdUSU6JRWK=
COLO-679 M1zQbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVy4RYtGUUN3ME2xOU42ODFizszN NH3QNXhUSU6JRWK=
JAR M3u4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTF3LkeyNFUh|ryP M2i1WXNCVkeHUh?=
NCI-H1666 NWniXm9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTF3LkmzPVkh|ryP MX\TRW5ITVJ?
SW48 NWHrWlZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\OTWM2OD1zNT65OVE3KM7:TR?= M{XrcHNCVkeHUh?=
NCI-H720 NIT6UpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPETGtXUUN3ME2xOU46QTh7IN88US=> MoXkV2FPT0WU
HT-1197 M4jTZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DNWmlEPTB;MU[uNFM2OiEQvF2= MV3TRW5ITVJ?
HL-60 NEnueFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjrfGRZUUN3ME2xOk4xOzh2IN88US=> NWjXUoNuW0GQR1XS
BEN NFPyPZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPFTWM2OD1zNj61OlM5KM7:TR?= NHHNfJFUSU6JRWK=
HAL-01 NEnacopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mme1TWM2OD1zNj64PVA6KM7:TR?= MYLTRW5ITVJ?
SW900 NHv1WpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzPboFxUUN3ME2xOk46OTN{IN88US=> MX3TRW5ITVJ?
SBC-1 NFnLPHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;HO2lEPTB;MUeuOVQzQSEQvF2= M{jINHNCVkeHUh?=
SH-4 NH61[49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zhZ2lEPTB;MUeuOVg1OSEQvF2= MVPTRW5ITVJ?
UACC-62 M{nj[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\XRohKSzVyPUG3Mlc3OzdizszN NEn6dHFUSU6JRWK=
BHT-101 NWnvS3VsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTF7Lki3NFUh|ryP MYPTRW5ITVJ?
DB NUPRTFl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XWWmlEPTB;MkGuOVY1QSEQvF2= NWW3XoliW0GQR1XS
SK-MEL-1 NFTnZo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWL3SpJSUUN3ME2yNU42QDd{IN88US=> MlO4V2FPT0WU
NCI-H747 MlTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLwbXdKSzVyPUKyMlc{PzlizszN NUXmXJZ7W0GQR1XS
SK-LU-1 MmnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTBTWM2OD1{Mz6zOVI1KM7:TR?= MkTYV2FPT0WU
KG-1 M2PmZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{L0fGlEPTB;MkOuOFk1PiEQvF2= NXjKNWM2W0GQR1XS
LXF-289 NH\BVnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvQTWM2OD1{Mz63NVQh|ryP NIr6cXVUSU6JRWK=
HCC1954 NH3OT3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrQ[I1wUUN3ME2yOE45QDR2IN88US=> NW\Yc|Q5W0GQR1XS
Ramos-2G6-4C10 NWHYV2JHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfFTWM2OD1{Nj60PVgyKM7:TR?= M1PreXNCVkeHUh?=
DBTRG-05MG MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTJ4Lk[0PFgh|ryP NF7NbY9USU6JRWK=
NCI-H2052 M1Po[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJ5LkW2PFQh|ryP NWK0ZpNmW0GQR1XS
RMG-I MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvaTWM2OD1{OT60NVM6KM7:TR?= NVfBeFZyW0GQR1XS
H9 M4DpOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXH[|I5UUN3ME2zNU4{ODB6IN88US=> MWHTRW5ITVJ?
GR-ST M4XHXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3j2VGlEPTB;M{KuOFQ2OyEQvF2= MUfTRW5ITVJ?
Mo-T MkTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDZe21KSzVyPUOyMlUxPDZizszN NHvUSHBUSU6JRWK=
SW1088 M3jMfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDuUHdiUUN3ME2zNk46QDBzIN88US=> MoLYV2FPT0WU
LB2518-MEL Mn\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3DeoNJUUN3ME2zN{4xPzl5IN88US=> MYnTRW5ITVJ?
NCI-H82 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILH[VJKSzVyPUOzMlE3PjFizszN MkX3V2FPT0WU
LAMA-84 MkfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTN2Lk[wO|Mh|ryP NHWwU2VUSU6JRWK=
KYSE-450 M2rxU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPQTWM2OD1|ND62O|c3KM7:TR?= Ml\PV2FPT0WU
LU-99A NFf1UFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnjVIJLUUN3ME2zOU4xODB5IN88US=> NEniWY9USU6JRWK=
BE-13 NWriUJRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHBTFNKSzVyPUO1MlY2PDVizszN M4T0PHNCVkeHUh?=
GAK M4\IU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFL0dmRKSzVyPUO1MlY6PSEQvF2= NXuweoF6W0GQR1XS
NCI-H1573 NIWyWmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTN3Lki4NVgh|ryP M{TFbXNCVkeHUh?=
AsPC-1 MoG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3S0OWlEPTB;M{[uNVUzPyEQvF2= MV;TRW5ITVJ?
HDLM-2 NGPUe4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTN4LkOxOkDPxE1? NHy0cphUSU6JRWK=
NCI-H441 NF7SfVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3pTWM2OD1|Nz6wOlkyKM7:TR?= NFuz[pRUSU6JRWK=
CAL-27 NXfUO|g4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTN5LkeyN|Eh|ryP MlHtV2FPT0WU
OVCAR-3 NIDORYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fkOGlEPTB;M{muN|E5OSEQvF2= MV\TRW5ITVJ?
RPMI-8226 NVjab3h2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjTTWM2OD1|OT61PVgh|ryP MWjTRW5ITVJ?
EFO-21 NV;DNGk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLmNVVKSzVyPUSwMlU5OTRizszN M3H0fXNCVkeHUh?=
SNU-C2B M{e4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHX3TXdKSzVyPUSxMlUxQDRizszN NGDHZWtUSU6JRWK=
VM-CUB-1 NXLTV25lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;TPWlEPTB;NEOuPFA{PyEQvF2= NW\ZcoJ2W0GQR1XS
NCI-H2087 NWP6Vnh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnG3TWM2OD12NT6wNlM{KM7:TR?= M1\WfHNCVkeHUh?=
EW-16 NITPfGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zx[GlEPTB;NE[uN|E{PyEQvF2= MY\TRW5ITVJ?
SK-N-AS MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHxTWM2OD12Nj63NVY4KM7:TR?= Mlv5V2FPT0WU
COR-L105 M{fJbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vufWlEPTB;NE[uPFg2PyEQvF2= M2Pt[XNCVkeHUh?=
DEL M2jVTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTR6LkC0Nlkh|ryP Mn;JV2FPT0WU
JVM-2 M{f4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1G2S2lEPTB;NEiuNFU2QCEQvF2= NHe3b|RUSU6JRWK=
KARPAS-45 NF;VNYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moi5TWM2OD12OT60OVM5KM7:TR?= MW\TRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / MDM2 / p21 / Bax / Bak / Noxa / cleaved caspase / pro-caspase; 

PubMed: 16014563     


Expression of apoptosis- and cell-cycle–associated proteins in OCI-AML-3 cells, which were treated with 5 μM Nutlin-3a for the indicated times. Nutlin-3a induced increased protein expression of p53, MDM2, and p21 in OCI-AML-3 cells in a time-dependent fashion. Nutlin-3a induced Noxa, a BH3-only member of the Bcl-2 family, followed by caspase activation. β-actin was used to confirm equal loading of proteins. Arrowheads indicate cleared caspases.

BMI-1; 

PubMed: 26887044     


Western blot analysis of BMI-1 and actin was performed in BV-173, SUP-B15, NALM-6, NALM-19 and REH cell lines after 24 hours treatment with increasing concentrations of Nutlin-3a (1 μM, 2 μM, 5 μM) and with DMSO control. 

p53-Ser15 / p53-Ser37 / p53-Lys382 / MDM2 / CDC2 / PLK1 / HSC70; 

PubMed: 23666059     


Expression of the indicated proteins in whole-cell lysates of cells treated for 96 h with 50 μM resveratrol (R), 5 μM nutlin-3a (N), or co-treated with both substances (RN).

16014563 26887044 23666059
Immunofluorescence
p-p21 / β-actin; 

PubMed: 31083332     


Cells were treated with fluoride (5 mM) with/without Nutlin-3a for 24 h. p-p21 (green), nucleus (DAPI; blue) and β-actin (red) expression were detected by immunocytochemistry. Nutlin-3a addition augmented p-p21 expression compared to NaF treatment alone.

P53; 

PubMed: 21394100     


At 12 h following treatment with nutlin-3a, DoHH2 and MCA cells had increased levels of p53 visualized by immunofluorescence. p53 localization was predominantly nuclear. The 4',6-diamidino-2-phenylindole was used as counterstain of the nuclei.

Ac-p300; 

PubMed: 30240745     


HepG2 cells were treated with 5 μM Nutlin-3a for 24 hr, and the levels of Ac-p300 and p53 were assessed by co-immunofluorescence. Fluorescence intensity of Ac-p300 in control cells versus Nutlin-3a-treated cells have been quantified (represented as mean ± SD, unpaired two-tailed Student's t test, n = 50 of three independent experiments). Scale bar, 10 μm.

31083332 21394100 30240745
Growth inhibition assay
Cell viability; 

PubMed: 26248031     


All 15 cell lines were plated in 96-well plates. After 24h, media was exchanged and cells were treated with incremental concentrations of Nutlin-3a (1 μM, 5 μM, 10 μM, 25 μM, 50 μM, and 70 μM). After 72h of Nutlin-3a treatment, cell viability was measured by WST assay and compared to untreated control.

26248031
In vivo Nutlin-3a suppresses xenograft growth in a dose-dependent fashion with the highest dose (200 mg/kg) showing a substantial tumor shrinkage [1]. Nutlin-3 is a selective activator of the p53 pathway in vivo and highly efficacious against SJSA-1 osteosarcoma tumors[1]. Tumors with wild-type p53 and mdm2 gene amplification will respond best to therapy with Nutlin-3a.

Protocol

Kinase Assay:[3]
- Collapse

Biacore studies:

Competition assays are performed on a Biacore S51. A Series S Sensor chip CM5 is derivatized for immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~ 200 response units (1 response unit corresponds to 1 pg of protein per mm 2). The concentration of MDM2 protein is kept constant at 300 nM. Test compounds are dissolved in DMSO at 10 mM and further diluted to make a concentration series of inhibitor in each MDM2 test sample. The assays are run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of inhibitor is calculated as a percentage of binding in the absence of inhibitor and IC50 is calculated using Microsoft Excel
Cell Research:[2]
- Collapse
  • Cell lines: OSA, T778, RMS13, U2OS, SaOS-2
  • Concentrations: ~5 μM
  • Incubation Time: 120 h
  • Method: SRB
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: SJSA-1 xenograft
  • Dosages: 50, 100, 200 mg/kg twice daily
  • Administration: oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.97 mM)
Ethanol 100 mg/mL (171.97 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+55% PEG 300+ddH2O
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.49
Formula

C30H30Cl2N4O4

CAS No. 675576-98-4
Storage powder
in solvent
Synonyms (-)-Nutlin-3
Smiles CC(C)OC1=C(C=CC(=C1)OC)C2=NC(C(N2C(=O)N3CCNC(=O)C3)C4=CC=C(C=C4)Cl)C5=CC=C(C=C5)Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the difference between S1061 (Nutlin-3) and S8059 (Nutlin-3a)?

  • Answer:

    S1061 is a racemic mixture of Nutlin3a and Nutlin3b. s8059 is the active enantiomer of Nutlin3.

Mdm2 Signaling Pathway Map

Related Mdm2 Products

Tags: buy Nutlin-3a | Nutlin-3a supplier | purchase Nutlin-3a | Nutlin-3a cost | Nutlin-3a manufacturer | order Nutlin-3a | Nutlin-3a distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID